Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 28832986

Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Cancer
Publication date
2017 Dec 1
First author
Samuels BL

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Samuels BL
      type
      Author
    2. name
      Chawla SP
      type
      Author
    3. name
      Somaiah N
      type
      Author
    4. name
      Staddon AP
      type
      Author
    5. name
      Skubitz KM
      type
      Author
    6. name
      Milhem MM
      type
      Author
    7. name
      Kaiser PE
      type
      Author
    8. name
      Portnoy DC
      type
      Author
    9. name
      Priebat DA
      type
      Author
    10. name
      Walker MS
      type
      Author
    11. name
      Stepanski EJ
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Samuels BL
      type
      Author
    2. name
      Chawla SP
      type
      Author
    3. name
      Somaiah N
      type
      Author
    4. name
      Staddon AP
      type
      Author
    5. name
      Skubitz KM
      type
      Author
    6. name
      Milhem MM
      type
      Author
    7. name
      Kaiser PE
      type
      Author
    8. name
      Portnoy DC
      type
      Author
    9. name
      Priebat DA
      type
      Author
    10. name
      Walker MS
      type
      Author
    11. name
      Stepanski EJ
      type
      Author
    bibliography ids
    1. nci-bib-ba3c532e59d87ee1597dda0b
    book metadata
    content sha256
    7c7313a23fb252f4b34d5189633a4b5e81dced809f29d5bbf07236f1d455edf2
    document type
    citation
    dois
    1. 10.1002/cncr.30926
    electronic publication date
    display
    2017 Aug 18
    precision
    day
    year
    2017
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:28832986
    immutable id
    pubmed:28832986@7c7313a23fb252f4b34d5189633a4b5e81dced809f29d5bbf07236f1d455edf2
    journal
    abbreviation
    Cancer
    issn electronic
    1097-0142
    issn print
    0008-543X
    issue
    23
    name
    Cancer
    nlm unique id
    0374236
    pages
    4640-4647
    volume
    123
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      28832986
      provenance
      batch id
      fb25b16edcb1373b70c1
      provider
      NCBI PubMed ESummary
      record sha256
      fbee21f6bec5472bd39bb621626ed39044556c9705b25deb1f7da24084bb3ecc
      response sha256
      182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
      retrieved at
      2026-09-09T23:47:28.490065+00:00
      publication date
      display
      2017 Dec 1
      precision
      day
      year
      2017
      publication types
      1. Clinical Trial, Phase II
      2. Journal Article
      3. Multicenter Study
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/28832986/
      title
      Results of a prospective phase 2 study of pazopanib in patients with advanced intermediate-grade or high-grade liposarcoma.

      Preserved source evidence · Not medical advice